No Data
No Data
Zai Lab Reports Lesser Loss in 2023
Zai Lab (HKG:9688) posted a net loss of $334.6 million for the year ended Dec. 31, 2023, compared with a loss of $443.4 million in the previous year, according to a Thursday Hong Kong bourse filing. T
Zaiding Pharmaceutical (09688) announced annual results, with total product revenue of US$266.7 million, an increase of 25% over the previous year
Zaiding Pharmaceutical (09688) announced its 2023 annual results, with product revenue of US$267 million, an increase of 25 million dollars over the previous year...
ZAI LAB: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients
Zai Lab's (ZLAB) and Novocure (NVCR) said Wednesday that the phase 3 METIS trial met its primary endpoint, showing that Tumor Treating Field therapy with supportive care significantly prolongs the tim
Zai Lab Partner Novocure's Metis Phase 3 Trial Meets Primary Endpoint In Brain Metastases
Novocure (NVCR.US) stock price surged, and its “tumor electric field therapy” phase 3 trial reached the main end
The Zhitong Finance App learned that on Wednesday, the stock price of Novocure (NVCR.US), a research and development company in the field of cancer treatment, once soared more than 40% to 18.660 US dollars during pre-market trading of US stocks, and rose more than 12% to 14.790 US dollars at the beginning of the opening of the market. Earlier, the company said that the phase 3 clinical trial of its cancer treatment method “TTFields” (also known as “tumor electric field therapy”) in patients with lung cancer brain metastases reached a major end. TTFields' partner in the Chinese market under Novocure (ZLAB.US)
No Data